
Quarterly report 2025-Q3
added 11-14-2025
Precipio EPS Ratio 2011-2026 | PRPO
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Precipio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.51 | -10.7 | -0.4 | -0.85 | -2.33 | -0.92 | -7.16 | -0.35 | -2.78 | -2.01 | -2.3 | -1.55 | -0.22 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.22 | -10.7 | -2.78 |
Quarterly EPS Ratio Precipio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | 0.05 | -0.59 | - | -0.42 | -0.83 | -1.46 | - | -1.04 | -1.88 | -2.61 | - | -2.79 | -0.09 | -0.2 | - | -0.08 | -0.14 | -0.08 | - | -0.21 | -0.2 | -0.78 | - | -0.31 | -1.05 | -0.48 | - | -2.49 | -2.29 | -7.1 | - | -1.36 | -15.3 | -1.69 | - | -1.15 | -1.03 | -0.18 | - | -0.55 | -0.3 | -0.36 | -0.77 | -0.05 | -0.57 | -0.6 | -0.57 | -0.78 | -0.41 | -0.54 | -0.42 | -0.04 | -0.01 | -0.05 | - | -0.03 | -0.13 | -0.06 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.05 | -15.3 | -1.13 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-2.06 | - | -6.23 % | $ 30.6 M | ||
|
Brainsway Ltd.
BWAY
|
-0.24 | $ 22.96 | -0.56 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
-14.2 | $ 23.25 | -0.66 % | $ 250 M | ||
|
Akumin
AKU
|
-1.75 | - | -17.87 % | $ 25.9 M | ||
|
Biocept
BIOC
|
-1.89 | - | -13.05 % | $ 7.29 M | ||
|
Accelerate Diagnostics
AXDX
|
-0.14 | - | -61.36 % | $ 2.46 M | ||
|
BioNano Genomics
BNGO
|
-88.1 | $ 1.59 | -0.94 % | $ 2.02 M | ||
|
Chembio Diagnostics
CEMI
|
-0.72 | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
4.3 | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
-1.2 | $ 6.12 | - | $ 180 M | ||
|
Global Cord Blood Corporation
CO
|
4.12 | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
-0.08 | - | - | $ 7.1 B | ||
|
Castle Biosciences
CSTL
|
0.66 | $ 39.59 | -0.76 % | $ 1.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.08 | - | 0.12 % | $ 80.1 M | ||
|
CareDx, Inc
CDNA
|
-3.54 | $ 17.02 | -1.16 % | $ 915 M | ||
|
Danaher Corporation
DHR
|
5.33 | $ 237.64 | 1.12 % | $ 174 B | ||
|
Celcuity
CELC
|
-2.83 | $ 107.43 | 2.63 % | $ 4.24 B | ||
|
DermTech
DMTK
|
-3.09 | - | -11.32 % | $ 2.94 M | ||
|
DarioHealth Corp.
DRIO
|
1.93 | $ 12.15 | -5.81 % | $ 345 M | ||
|
Anixa Biosciences
ANIX
|
-0.39 | $ 3.41 | -0.29 % | $ 109 K | ||
|
DexCom
DXCM
|
1.4 | $ 66.95 | -2.16 % | $ 25.8 B | ||
|
Enzo Biochem
ENZ
|
-0.51 | - | -8.98 % | $ 14.8 K | ||
|
QIAGEN N.V.
QGEN
|
0.38 | $ 48.32 | -0.27 % | $ 10.8 B | ||
|
Exact Sciences Corporation
EXAS
|
-4.67 | $ 102.13 | 0.34 % | $ 18.9 B | ||
|
Fulgent Genetics
FLGT
|
-1.41 | $ 27.84 | -0.2 % | $ 842 M | ||
|
Aspira Women's Health
AWH
|
-0.23 | - | -6.19 % | $ 10.5 M | ||
|
Guardant Health
GH
|
-3.56 | $ 110.18 | 1.32 % | $ 13.5 B | ||
|
Charles River Laboratories International
CRL
|
0.2 | $ 220.64 | 2.38 % | $ 11.3 B | ||
|
Heska Corporation
HSKA
|
-1.92 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-24.3 | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
-7.69 | $ 141.01 | -3.31 % | $ 22.4 B | ||
|
IQVIA Holdings
IQV
|
7.57 | $ 243.33 | 0.06 % | $ 44.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
7.78 | $ 175.1 | -1.49 % | $ 19.4 B | ||
|
Biodesix
BDSX
|
-0.33 | $ 5.46 | -2.15 % | $ 708 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.89 | $ 252.61 | -0.81 % | $ 21.2 B | ||
|
ICON Public Limited Company
ICLR
|
9.6 | $ 183.13 | -2.7 % | $ 15.1 B | ||
|
IDEXX Laboratories
IDXX
|
10.8 | $ 715.47 | 0.43 % | $ 59 B | ||
|
Lantheus Holdings
LNTH
|
4.52 | $ 67.98 | 0.19 % | $ 4.7 B | ||
|
Agilent Technologies
A
|
3.98 | $ 148.92 | 2.17 % | $ 45.3 B | ||
|
Biomerica
BMRA
|
-2.16 | $ 2.75 | -4.84 % | $ 6.32 M | ||
|
Bioventus
BVS
|
-2.49 | $ 8.02 | 0.25 % | $ 502 M | ||
|
Koninklijke Philips N.V.
PHG
|
3.67 | $ 29.59 | 0.54 % | $ 20 B | ||
|
Motus GI Holdings
MOTS
|
-15.9 | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
40.7 | $ 1 486.09 | 1.43 % | $ 31.5 B | ||
|
Myriad Genetics
MYGN
|
-1.41 | $ 6.53 | -0.53 % | $ 592 M | ||
|
ENDRA Life Sciences
NDRA
|
-5.55 | $ 4.6 | -0.44 % | $ 2.47 M |